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ABSTRACT
Purpose To examine the immunogenicity of diphtheria tox-
oid (DT) loaded mesoporous silica nanoparticles (MSNs) after
coated and hollow microneedle-mediated intradermal immu-
nization in mice.
Methods DT was loaded into MSNs and the nanoparticle
surface was coated with a lipid bilayer (LB-MSN-DT). To
prepare coated microneedles, alternating layers of negatively
charged LB-MSN-DT and positively charged N-trimethyl
chitosan (TMC) were coated onto pH-sensitive microneedle
arrays via a layer-by-layer approach. Microneedle arrays
coated with 5 or 3 layers of LB-MSN-DT were used to im-
munize mice and the elicited antibody responses were com-
pared with those induced by hollow microneedle-injected liq-
uid formulation of LB-MSN-DT. Liquid DT formulation
with and without TMC (DT/TMC) injected by a hollow
microneedle were used as controls.
Results LB-MSN-DT had an average size of about 670 nm
and a zeta potential of −35 mV. The encapsulation efficiency
of DT in the nanoparticles was 77%. The amount of nano-
encapsulated DT coated onto the microneedle array in-
creased linearly with increasing number of the coating layers.
Nano-encapsulated DT induced stronger immune responses
than DT solution when delivered intradermally via hollow
microneedles, but not when delivered via coated
microneedles.
Conclusion Both the nano-encapsulation of DT and the type
of microneedles affect the immunogenicity of the antigen.
KEY WORDS coatedmicroneedles . diphtheria toxoid .
hollowmicroneedles . intradermal vaccination .mesoporous silica
nanoparticles
ABBREVIATIONS
APCs Antigen-presenting cells
CLSM Confocal laser scanning microscopy
DLS Dynamic light scattering
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine
DOPS 1,2-dioleoyl-sn-glycero-3-[phospho-L-
serine](sodium salt)
DT Diphtheria toxoid
EE Encapsulation efficiency
LB-MSN-DT DT loaded and lipid fused MSNs
LC Loading capacity
MSNs Mesoporous silica nanoparticles
PB Phosphate buffer
PBS Phosphate buffered saline
PDI Polydispersity index
SEM Scanning electronic microscopy
TMB 3,3′,5,5′-tetramethylbenzidine
TMC N-trimethyl chitosan
INTRODUCTION
Vaccination is one of the most cost-effective tools to prevent
infectious diseases in human beings (1). Traditional vaccines
are based on attenuated or inactivated pathogens. Nowadays,
subunit vaccines containing only immunogenic parts of a
pathogen are being extensively investigated because they are
safer (2). The disadvantage of subunit vaccines is that they are
generally less immunogenic than traditional vaccines. To
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overcome this, adjuvants such as immune modulators and
nanoparticulate delivery systems can be used (3,4).
Nanoparticles have been extensively studied for the deliv-
ery of vaccines, as they can improve the immunogenicity of
antigens by enhancing the targeting of antigens to antigen-
presenting cells (APCs) (5). Furthermore, the immune re-
sponses can potentially be modified by tuning the properties
of nanoparticles such as size, surface charge, and release ki-
netics of antigens (3,6,7). Among different types of nanoparti-
cles, mesoporous silica nanoparticles (MSNs) have gained in-
creasing attention because of their excellent biocompatibility
and stability. Besides, the silica surface can be easily modified
and functionalized and the large pores and surface area of
MSNs enable efficient loading of antigens with a high loading
capacity (8,9). Studies have shown that antigen loaded MSNs
are able to increase the uptake of antigens by APCs and im-
prove immune responses in mice (9–11).
Vaccines are mostly administered by intramuscular or sub-
cutaneous injection, but these methods have disadvantages
such as low acceptance by a considerable number of people
and infection risk due to needlestick injuries or reuse of needles
(12–14). Additionally, the delivery of vaccines to APCsmay be
inefficient as these delivery sites are not rich of APCs (15). To
avoid the drawbacks of hypodermic needles, microneedles
have been developed. Microneedles are micrometer-sized
needle-like structures and can be used to penetrate skin and
deliver the antigen in a minimal invasive and pain-free way
(16). The skin contains a large number of APCs, and therefore
microneedle-mediated intradermal delivery of vaccines has
potential for effective vaccination (17).
Several types of microneedles are in development, such as
coated, dissolvable and hollow microneedles (16). On the one
hand, coated and dissolvable microneedles are used to admin-
ister dry-state vaccine formulations (18), which offer the po-
tential advantage of improving antigen stability (16,19).
Previously, silicon microneedle arrays with a pH-sensitive sur-
face were developed to bind negatively charged vaccines at
slightly acidic conditions (pH 5.8) and release the coated ma-
terial at physiological pH (7.4) (20). Several studies have
shown that the antigen coated microneedles induced a similar
immune response as subcutaneously or intramuscularly
injected antigen solution (21–23). On the other hand, hollow
microneedles are used to inject liquid formulations and the
dose can be precisely controlled. We previously showed that
hollow microneedles together with an applicator can be used
to deliver antigen-loaded nanoparticles intradermally (24).
In this study, we aimed to examine the immunogenicity of
intradermally delivered DT loaded MSNs by using either
coated microneedle arrays or a single hollow microneedle.
The microneedle arrays were coated with DT loaded in
MSNs by using a layer-by-layer coating approach after which
the delivered dose into ex vivo human skin was examined. In a
subsequent immunization study, the antibody response
induced by LB-MSN-DT coated microneedles was compared
with that obtained after injection of a suspension of LB-MSN-
DT by hollow microneedles into mouse skin.
MATERIALS AND METHODS
Materials
DT (batch 04–44, 1 μg equal to 0.3 Lf) and diphtheria toxin
were provided by Intravacc (Bilthoven, The Netherlands). (3-
aminopropy l ) t r i e thoxys i lane (APTES, 99%) , 4 -
pyridinecarboxaldehyde (97%), sodium cyanoborohydride
(NaBH3CN, 95%), cholesterol (≥99%), fetal bovine serum
(FBS), M199 medium (with Hank’s salts and L-glutamine)
and bovine serum albumin (BSA) were obtained from
Sigma-Aldrich (Zwijndrecht, The Netherlands). 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-
glycero-3-[phospho-L-serine](sodium salt) (DOPS) were pur-
chased from Avanti Polar Lipids Inc. (Alabaster, AL).
Hydrogen peroxide (30%) was purchased from Fluka
(Steinheim, Germany). Toluene (≥99.7%) was obtained from
Biosolve (Valkenswaard, The Netherlands). N-trimethyl chi-
tosan (TMC) and rhodamine labeled TMC (TMC-Rho) were
prepared as reported previously (23,25). Glucose solution, L-
glutamine (200 nM), penicillin-streptomycin (10,000 U/mL)
and 1-step™ ultra 3,3′,5,5′-tetramethylbenzidine (TMB) were
purchased from Thermo-Fisher Scientific (Waltham, MA).
IRDye 800CW protein labeling kit (low molecular weight)
was ordered from LI-COR (Lincoln, NE). HRP-conjugated
goat anti-mouse total IgG, IgG1 and IgG2a were ordered
from Southern Biotech (Birmingham, AL). Sulfuric acid (95–
98%) was ob ta ined f rom JT Baker (Deven t e r ,
The Netherlands). Sterile phosphate buffered saline (PBS,
163.9 mM Na+, 140.3 mM Cl−, 8.7 mM HPO4
2−, 1.8 mM
H2PO
4−, pH 7.4) was ordered from B. Braun (Oss,
The Netherlands). 1 mM phosphate buffer (PB) with a pH
of 7.4 or 5.8 was prepared in the lab. Milli-Q water
(18 MΩ/cm, Millipore Co.) was used for the preparation of
all solutions. All the other chemicals used were of analytical
grade.
Preparation of DT Encapsulated and Lipid Fused MSNs
(LB-MSN-DT)
Plain MSNs with a particle size of about 200 nm and large
pores (about 10 nm in diameter) were prepared and modified
with amino groups to generate a positively charged surface, as
described earlier (11,26). To improve the colloidal stability of
MSNs, liposomes were coated onto the surface of MSNs by
using a method as previously described (11). These liposomes
were prepared by lipid film hydration followed by sonication.
Briefly, DOPC, DOPS and cholesterol with a molar ratio of
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7:1:2 were dissolved in chloroform in a round bottom flask.
The organic solvent was evaporated by using a rotary evapo-
rator (Buchi rotavapor R210, Flawil, Switzerland) for 30 min.
Subsequently, the lipid film was hydrated with 1 mM PB
(pH 7.4) and vortexed for 10 s to form a lipid vesicle suspen-
sion. The suspension was sonicated in a Branson 2510 water
bath (Danbury, CT) for 10min. The obtained liposomes were
stored at 4°C in the refrigerator for further use.
To prepare LB-MSN-DT, 0.5 mL MSNs (2 mg/mL) and
0.5 mL DT (0.5 mg/mL) were mixed in 1 mM PB (pH 7.4),
followed by addition of 0.5 mL liposomes (2 mg/mL) in
1 mM PB (pH 7.4). To prepare LB-MSN-DT loaded with
Alexa488 or IRDye 800CW labeled DT, plain DT was re-
placed with fluorescently labeled DT according the need of
experiments. The mixture was incubated in an Eppendorf
thermomixer (Nijmegen, The Netherlands) for 1.5 h at 25°C
with a speed of 300 rpm. To remove the excess DT and
liposomes, the suspension was centrifuged by using a Sigma
1–15 centrifuge (Osterode, Germany) for 5 min with a speed
of 10,000 g. The resultant pellet was washed and re-dispersed
in 1 mM PB (pH 7.4) for further use.
Measurement of Size and Zeta Potential
of LB-MSN-DT
The size and zeta potential of LB-MSN-DT were determined
by using dynamic light scattering (DLS) and laser Doppler
velocimetry, respectively, with a Nano ZS® zetasizer
(Malvern Instruments, Worcestershire, U.K.). The samples
were diluted in 1 mM PB (pH 7.4) to a concentration of
25 μg/mL (expressed based on the concentration of MSNs)
and measured 3 times with 10 runs for each measurement.
Determination of Encapsulation Efficiency (EE)
and Loading Capacity (LC) of DT in LB-MSN-DT
The loading efficiency of DT was determined by measuring
the intrinsic fluorescence intensity of DT ((λex 280 nm/λem
320 nm) in the supernatant before and after encapsulation
by using a Tecan M1000 plate reader (Männedorf,
Switzerland). The EE and LC were calculated using the equa-
tions below:
EE ¼ Mloaded DT
Mtotal DT
 100%
LC ¼ Mloaded DT
MMSNs
 100%
Where Mloaded DT represents the mass of encapsulated DT,
Mtotal DT is the total amount of DT added to the formulation
and MMSNs is the weight of MSNs.
In Vitro Release of DT from LB-MSN-DT
To study the release of DT, 1 mL nanoparticle suspension
with a concentration of 1 mg/mL (expressed based on the
concentration of MSNs, corresponding to about 0.2 mg/mL
DT) in PBS was incubated for one month at 37°C by using an
Eppendorf thermomixer (Nijmegen, The Netherlands) set at a
speed of 550 rpm. At predetermined time points, the samples
were centrifuged for 5 min with a speed of 10,000 g. 600 μL
sample from the supernatant was collected and the amount of
DT was measured by intrinsic fluorescence intensity of DT.
Fresh PBS with the same volume of the collected supernatant
was added back to the suspension. The release percentage of
DT was calculated by dividing the released amount of DT by
the total amount of DT initially loaded in LB-MSN-DT.
Modification of Microneedle Arrays to Achieve
a PH-Sensitive Surface
Silicon microneedle arrays with 576 microneedles per array
on a back plate of 5 × 5 mm2 with a microneedle length of
200 μm were kindly provided by Robert Bosch GmbH
(Stuttgart, Germany). To obtain pH-sensitive microneedles,
the surface was modified with pyridine groups as previously
reported (20). In brief, the microneedle surface was first
cleaned by piranha solution (70% sulfuric acid and 30% hy-
drogen peroxide) at 120°C for 2 h. Caution: piranha is strongly
acidic and oxidizing. Piranha reacts violently with organic compounds,
and it should not be stored in closed containers. Subsequently, the
microneedles were extensively washed with MilliQ water
followed by washing with acetone and methanol. Next, the
microneedles were incubated in 2% APTES in toluene over-
night to obtain an amine-modified surface and thereafter in-
cubated with 4-pyridinecarboxaldehyde (100 mM) in anhy-
drous isopropanol containing 1% acetic acid overnight.
Finally, the formed imine bonds were reduced to secondary
amines by incubating the microneedles with NaBH3CN
(50 mM) in isopropanol for 2 h. After cleaning the
microneedles were stored under vacuum at 50°C until further
use.
Multilayer Coating of LB-MSN-DTon the Surface
of Microneedle Arrays
LB-MSN-DT and TMC were alternately coated onto the
surface of microneedle arrays by using a layer-by-layer ap-
proach. The pH-sensitive microneedle arrays were transferred
into Greiner Cellstar® 48 well plates. 50 μL negatively
charged LB-MSN-DT (0.5 mg/mL) in 1 mM PB (pH 5.8)
was added onto the top of each microneedle array and the
arrays were incubated for 30 min. The excess nanoparticles
were washed by adding 450 μL 1 mM PB (pH 5.8). Next, the
microneedle arrays were dried under pressurized nitrogen
Pharm Res  (2018) 35:189 Page 3 of 12  189 
flow for 10 min. After the first coating layer of LB-MSN-DT,
50 μL positively charged TMC (40 μg/mL) in 1 mM PB
(pH 5.8) was added onto the top of each microneedle array
and the arrays were incubated with TMC for another 30 min.
The concentration of LB-MSN-DT and TMC in the coating
solutions were chosen based on prior studies (11,23). The ex-
cess TMC was removed by washing the microneedle arrays
with 450 μL 1 mM PB (pH 5.8). Subsequently, the
microneedle arrays were dried under nitrogen flow as de-
scribed above. This procedure was repeated until the desired
number of coating layers of LB-MSN-DT was reached. After
the last layer of LB-MSN-DT, nomore TMCwas coated onto
the microneedle surface. In order to study the dose effect of
DT using coated microneedles, the microneedle arrays were
coated with either 5 or 3 layers of LB-MSN-DT and 4 or 2
alternate layers of TMC, respectively.
To determine the coating efficiency of DT on
microneedles, the amount of nano-encapsulated DT in the
supernatant after washing was determined by measuring the
intrinsic fluorescence of DT. The coating efficiency was cal-
culated by dividing the amount of coated DT by the total
amount of DT initially added to the coating solution.
Insertion of Microneedle Arrays into Ex Vivo Human
Skin
Ex vivo human skin was obtained from a local hospital accord-
ing to Helsinki principles. A written informed patient consent
was obtained. To reproducibly insert the microneedles into
the skin, an in-house developed impact-insertion injector to-
gether with a uPRAX applicator controller (Delft,
The Netherlands) was used by using either a single insertion
mode or multiple insertion mode (27,28). In case of a single
insertion, the microneedle arrays were inserted into the skin
with an average velocity of 0.5 m/s and kept in the skin for
30 min by applying a force of 5 N on top of the microneedle
array. In case of multiple insertion mode, the microneedle
arrays were 10 times inserted into the skin within 10 s with
an average velocity of 0.5 m/s. After the last penetration, the
microneedles were removed from the skin.
Visualization of the Coated Microneedles before and
after Penetration of Ex Vivo Human Skin by Scanning
Electronic Microscopy (SEM)
The 5-layer LB-MSN-DT coated microneedles were visual-
ized with a Nova NanoSEM (Eindhoven, The Netherlands)
operated with a voltage of 15 kV before and after removal
from the skin. To increase the surface conductivity, the
microneedle arrays were coated with a layer of platina/
palladium before visualization.
Release of LB-MSN-DT from Microneedle Arrays
into Ex Vivo Human Skin
To visualize the release of LB-MSN-DT from microneedle
arrays into the skin, the 5-layer LB-MSN-DT coated
microneedle arrays and the released nanoparticles in the skin
were visualized by using a Nikon D-Eclipse C1 CLSM
(Tokyo, Japan). For this purpose, DT-Alexa488 and TMC-
Rho were used. The coated microneedles and the skin area
penetrated by coatedmicroneedles were scanned with a depth
resolution of 5 μm/step by using a 10 × and 4 × Plan Apo
objective, respectively. An argon laser (488 nm) with a 530/
55 emission filter and a diode-pumped solid-state laser
(561 nm) with a 590/55 emission filter were used for visuali-
zation of DT-Alexa488 and TMC-Rho, respectively.
The released amount of DT in the ex vivo human skin was
quantified by using a Perkin-Elmer IVIS Lumina Series III
in vivo imaging system (Waltham,MA, USA). For this purpose,
DT was labeled with IRDye 800 CW (DT-IRDye800) by
using a IRDye 800CW protein labeling kit (low molecular
weight) according to the manufacturer’s instruction. The
LB-MSN-DT-IRDye800 coated microneedles were inserted
into human skin by using either the single ormultiple insertion
mode as described above. A calibration curve was prepared
by injecting different amounts of LB-MSN-DT-IRDye800 in
the skin by using a hollow microneedle (see below). To deter-
mine the amount of DT released from the coated
microneedles, the fluorescence intensity of DT-IRDye800 in
the skin was measured by using the in vivo imaging system with
a 745 nm excitation wavelength and an ICG emission filter.
By using the calibration curve the amount of delivered DT
was calculated.
Hollow Microneedles and Applicator
The hollow microneedles were prepared by etching of fused
silica capillaries with hydrofluoric acid, as previously de-
scribed (29). In brief, silica capillaries (375 μm outer diameter,
50 μm inner diameter) were cut into 4-cm pieces and filled
with silicone oil in a vacuum oven (100°C) overnight. The tips
of capillaries were etched in ≥48% hydrofluoric acid for 4 h.
Subsequently, the polyimide coating was removed by dipping
the microneedle tips into hot sulfuric acid (250°C) for 5 min.
The applicator for hollow microneedles consists of a syringe
pump and an injector for precise control of injection depth,
rate and volume. The hollow microneedles, injector and
pump were connected by silica capillaries and high-pressure
resistant CapTite™ connectors (24).
Immunization Studies in Mice
Female BALB/c mice of 7–8 weeks old (Charles River,
Maastricht, The Netherlands) at the start of the experiments
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were used for the immunization study. The animals were
housed under standardized conditions in the animal facility
of Leiden Academic Centre for Drug Research. The study
was approved by the ethical committee on animal experi-
ments of Leiden University (Licence number 14166).
Mice were first anesthetized by intraperitoneal injection of
ketamine (60 mg/kg) and xylanize (4 mg/kg) before shaving
the abdomen area. In case of coated microneedles, the LB-
MSN-DT coated microneedle arrays were inserted into the
abdomen of mice by using the multiple insertion mode as
described above for the studies in ex vivo human skin. Each
mouse was immunized with one microneedle array coated
with either 5 or 3 layers of LB-MSN-DT. In case of hollow
microneedles, the following groups were included: a) 10 μL
suspension of LB-MSN-DT, b) 10 μl DT solution and c) 10 μl
DT and TMC solution. All formulations of hollow
microneedle groups contained 0.31 μgDT. The same amount
of TMC was included in the DT and TMC group. The for-
mulation was injected into the skin of the abdomen of mice
with a rate of 10 μL/min at a depth of 120 μm.
Subcutaneously injected 5 μg DT formulated with 150 μg
colloidal aluminum phosphate (DT-Alum) in PBS with a vol-
ume of 100 μL was used as a positive control. The mice were
immunized on day 0 (prime), 21 (1st boost), 42 (2nd boost) and
sacrificed on day 56. The serum was withdrawn from the tail
veins of the mice on day 0, 21 and 42 prior to the immuniza-
tion. On day 56 the serum was collected from femoral vein
and the mice were sacrificed by cervical dislocation.
Measurement of DT-Specific Antibody Titers
The total IgG and subtype IgG1 and IgG2a titers in the serum
were measured by using ELISA as previously reported (30).
Briefly, the wells of 96-well plates were first coated with 140 ng
DT overnight at 4°C. Next, the plates were blocked with 1%
BSA and appropriate 3-fold serial diluted serum samples were
applied to the plates and incubated for 2 h at 37°C.
Subsequently, HRP-conjugated goat anti-mouse total IgG,
IgG1 and IgG2a were added into the wells and incubated
for 1.5 h. Finally, TMB was added to the plates and 2 M
sulfuric acid was added to stop the reaction. The absorbance
was measured at 450 nm by using a Tecan M1000 plate
reader. The antibody titers were expressed as the 10log value
where the corresponding absorbance is located in the middle
of the S-shaped dilution-absorbance curve.
Measurement of DT-Neutralizing Antibody Titers
To check the functionality of the antibodies, diphtheria toxin
neutralizing antibody titers in the serum of the mice at day 56
were checked by using a Vero-cell assay (31). Briefly, appro-
priate 2-fold serial diluted serum was first applied to 96-well
plates. 5 × 10−5 Lf diphtheria toxin was added to each well
and incubated for 2 h at 37°C in a stove with 5% CO2.
Subsequently, 1.25 × 104 Vero cells were added to each well
and incubated for 6 days at 37°C in the stove with 5% CO2.
Finally, the neutralizing antibodies were shown as the 2log
value of the highest dilution times of serum that protected
the Vero cells.
Statistics Analysis
All the data of antibody titers were analyzed by one way
ANOVA with Newman-Keuls Multiple post-test by using
GraphPad Prism software (version 5.02). The level of signifi-
cance was set at *p< 0.05, **p< 0.01, ***p< 0.001.
RESULTS
Physicochemical Characteristics of LB-MSN-DT
The physicochemical characteristics of LB-MSN-DT are
shown in Table I. The size of LB-MSN-DTwas approximate-
ly 700 nmwith a polydispersity index (PDI) slightly larger than
0.3. The nanoparticles showed a high negative zeta potential.
DT was efficiently encapsulated into the nanoparticles with a
high EE and LC.
In Vitro Release of DT from LB-MSN-DT
The in vitro release of DT was investigated by suspending LB-
MSN-DT in PBS for one month. As shown in Fig. 1, there was
a moderate burst release of DT of about 20% within the first
day, followed by a sustained release, reaching a total release
percentage of about 70% on day 30. These results indicate
that the LB-MSN-DT may serve as a reservoir and allow the
sustained release of DT, but at the same time retain sufficient
DT for a prolonged period of time to deliver it as
nanoparticulate antigen to APCs.
Quantification of Coated Amount
of Nano-Encapsulated DTon Microneedle Arrays
As shown in Fig. 2a, the amount of nano-encapsulated DT
that was coated onto the microneedles increased linearly with
increasing number of coating layers. About 0.4 μg DT was
coated onto the microneedles of one microneedle array per
layer. The coating efficiency was similar for each layer and
was about 20–26% (Fig. 2b). As shown in Table II, the cumu-
lative amount of nano-encapsulated DT coated on the
microneedle surfaces of one microneedle array was about
1.9 μg and 1.1 μg, corresponding to 9.7 μg and 5.7 μg LB-
MSN-DT (based on the mass of MSNs) for a 5-layer and 3-
layer coating, respectively.
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Visualization of Coated Microneedles before and
after Penetrating Ex Vivo Human Skin by SEM
The 5-layer LB-MSN-DT coated microneedles were visual-
ized by SEM. The uncoated pH-sensitive microneedles
showed a smooth surface (Fig. 3a, b1-b2). On the surface of
LB-MSN-DT coated microneedles (Fig. 3 c1-c2), single nano-
particles or clusters of nanoparticles were observed. After in-
sertion of the microneedles into and removal from the skin,
the nanoparticle density was reduced on the microneedle sur-
face (Fig. 3 d1-d2).
Visualization of the Released LB-MSN-DT in Ex Vivo
Human Skin
After observation of the reduction of the number of nanopar-
ticles on the microneedle surface after penetration in and
withdrawal from human skin, CLSM was used to visualize
the released LB-MSN-DT in the skin. To this end, the 5-
layer LB-MSN-DT coated microneedles before penetration
of the skin were first visualized. The green color from DT-
Alexa488 (Fig. 4a) and red color from TMC-Rho (Fig. 4b)
were observed and they colocalized on the surface of the
microneedles (Fig. 4c). These results support the SEM images
of LB-MSN-DT coated microneedles (Fig. 3 c1-c2), further
revealing that LB-MSN-DT were successfully coated onto the
surface of the microneedles.
Next, the released LB-MSN-DT in the skin was visualized
by CLSM. After a single insertion, the fluorescence of the
released DT-Alexa488 and TMC-Rho were clearly observed
(Fig. 4d-f). The green color from DT-Alexa488 (Fig. 4d) and
red color from TMC-Rho (Fig. 4e) co-localized in the micro-
channels induced by the microneedles (Fig. 4f). After the
microneedles were inserted in and withdrawn from the skin
by using the multiple insertion mode, clearly more micro-
channels were observed as indicated by the fluorescence of
DT-Alexa488 and TMC-Rho (Fig. 4g-i). These results togeth-
er with the SEM images of the coated microneedles after
penetration of the skin indicate that LB-MSN-DT were suc-
cessfully released into skin.
Quantification of the Released Amount of DT
from Microneedles into Ex Vivo Human Skin
As shown in Table II, after insertion of the 5-layer coated
microneedle arrays into ex vivo human skin, the delivery effi-
ciency from the microneedles by using the multiple insertion
mode (42.8%) was more than twice as high compared to that
in single insertion mode (17.9%). Based on this observation,
the multiple insertion mode was chosen for subsequent pene-
tration studies. Next, the released amounts of DT from
microneedles coated with 5 and 3 layers of LB-MSN-DTwere
compared. The amount of delivered DT in the skin from one
5-layer coated microneedle array (0.814 μg) was about 3-fold
higher than that from a 3-layer coated microneedle array
(0.256 μg) (Table II).
IgG Antibody Titers after Intradermal Vaccination
Total IgG titers are shown in Fig. 5. On day 21 all groups
showed detectable total IgG titers (Fig. 5a). On day 42, the
responses of all groups increased compared to those on day
21. Responses of hollow microneedle injected LB-MSN-DT
were significantly higher than those induced by DT/TMC
solution and LB-MSN-DT coated microneedle groups (Fig.
5b) (p < 0.05). On day 21 and 42, DT-Alum induced higher
total IgG responses than other groups, probably due to the
much higher dose used (p< 0.01). On day 56, the responses of
hollow microneedle injected LB-MSN-DT and 5-layer LB-
MSN-DT coated microneedles increased to similar IgG levels
as those induced by DT-Alum, despite the ca. 15-fold lower
dose, while DT/TMC solution elicited significantly lower
levels than DT-Alum.
Fig. 1 In vitro release of DT from LB-MSN-DT in PBS at 37°C as a function
of time. Bars represent mean± SEM, n=3.
Table I Physicochemical
Characteristics of LB-MSN-DT
(n=3).
Nanoparticles Sizea (nm) PDIb ZPc (mV) EE%d LC%e
LB-MSN-DT 676± 7 0.322± 0.016 −35± 1 77.1± 6.4 19.3 ± 1.6
Data are average± SEM of 3 independent batches
a Size: Z-average in diameter, b PDI: polydispersity index, cZP: zeta potential, d EE: encapsulation efficiency, e LC: loading
capacity
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In all these three immunizations, the addition of TMC did
not improve the total IgG response. Additionally, 5-layer LB-
MSN-DT coated microneedles seemed to induce a stronger
total IgG response than 3-layer coatedmicroneedles, although
the difference was not significant (p˃0.05). In summary, LB-
MSN-DT delivered by both coated and hollow microneedles
successfully induced DT-specific total IgG responses. LB-
MSN-DT induced superior total IgG responses as compared
to DT/TMC solution when administered by hollow
microneedles (after 1st boost), but not when using coated
microneedles.
Besides total IgG, we measured the subtype IgG1 and
IgG2a titers. As shown in Fig. 6, IgG1 followed the trend of
total IgG (Fig. 6a, c, e). Hollow microneedle injected LB-
MSN-DT induced stronger responses than DT/TMC solu-
tion (after 1st boost). However, this advantage of using LB-
MSN-DT disappeared when LB-MSN-DT were delivered by
coated microneedles. In case of IgG2a titers, on day 21 all
groups except coated microneedles induced detectable
IgG2a titers (Fig. 6b). On day 42, DT-Alum induced signifi-
cantly higher titers than other groups (Fig. 6d) (p˂0.05).
Although not significant, hollow microneedle injected LB-
MSN-DT seemed to induce a higher IgG2a response com-
pared to DT solution (p= 0.10) and coated microneedles (p=
0.12). On day 56, hollow microneedle injected LB-MSN-DT
and DT solution showed significantly higher IgG2a titers than
3-layer LB-MSN-DT coated microneedle group (p˂0.01), but
this was not significant compared to 5-layer LB-MSN-DT
coated microneedles (Fig. 6f) (p = 0.15). Furthermore, the
IgG2a titers induced by hollow microneedle injected LB-
MSN-DT reached a level similar to those induced by DT-
Alum. In summary, hollow microneedle injected LB-MSN-
DT induced stronger IgG1 and IgG2a titers than LB-MSN-
DT coated microneedles.
The functionality of the antibody response was determined
by measuring the DT-neutralizing antibodies from serum tak-
en on day 56. As expected, the subcutaneously injected DT-
Alum with a high dose induced high neutralizing antibody
titers (Fig. 7). Hollow microneedle-injected LB-MSN-DT
showed a significant higher neutralizing response than a mix-
ture of DT and TMC solution and coated microneedle
groups.
DISCUSSION
Microneedle technologies for the intradermal delivery of
drugs, including vaccines, have been extensively investigated
during the past twenty years (32). As the skin contains a large
number of APCs, such as epidermal Langerhans cells and
dermal dendritic cells, microneedles have gained particular
attention as attractive delivery systems for intradermal vacci-
nation (33). In this study, we investigated the immunogenicity
of DT encapsulated MSNs after coated microneedle- and
hollow microneedle-mediated intradermal immunization in
mice. We showed that LB-MSN-DT delivered by both coated
Table II Coated and Released Amount of DT/LB-MSN-DT from the Microneedles of a Single Microneedle Array (n=3).
Microneedles Coated DT (μg) aCoated LB-MSN-DT (μg) bDelivered DT (μg) cDelivered percentage (%)
Multiple insertionmode Single insertionmode Multiple insertionmode Single insertionmode
5-layer coated 1.9± 0.1 9.7± 0.2 0.814± 0.008 0.341± 0.083 42.8± 0.1% 17.9± 0.8%
3-layer coated 1.1± 0.1 5.7± 0.2 0.256± 0.001 – 23.2± 0.0% –
Data are average± SEM of 3 independent microneedle arrays
a The coated amount of LB-MSN-DT is expressed as the mass of MSNs and was calculated by using the coated amount of DTand loading capacity of DT in LB-
MSN-DT
b The delivered dose of DTwas measured in ex vivo human skin
c Delivered percentage was calculated by dividing the delivered amount of DT in ex vivo human skin by the coated amount of DTon the microneedles
Fig. 2 Cumulative amount of
nano-encapsulated DT (a) that was
coated on the microneedles of one
microneedle array and coating effi-
ciency (b) as a function of the num-
ber of layers. Data is represented as
average± SEM of 3 independent
microneedle arrays.
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and hollow microneedles induced DT-specific antibody titers.
Both the nano-encapsulation of DT and the type of
microneedles were found to affect the immune responses.
Nanoparticulate vaccines have been reported to enhance
the immunogenicity of antigens by increasing their uptake by
APCs (3,34). In this study, MSNs were chosen for the loading
of DT as they have large pores which allow for efficient load-
ing of antigen (11). In a previous study it was shown that
ovalbumin (OVA) loaded MSNs were able to elicit antibody
responses with a reduced antigen dose compared to OVA
solution adjuvanted with QuilA (9). In another study, MSNs
loaded with a virus related antigen induced 10-fold higher
antibody responses than the mixture of the antigen and an
immune modulator (10). Our findings are in line with these
results, as we showed that hollow microneedle injected LB-
MSN-DT induced distinctly higher total IgG and IgG1 titers
as compared to a solution of plain DT.
When coating LB-MSN-DT onto the microneedle arrays,
the coated amount of DT per layer on one microneedle array
(about 500 ng) was higher than that reported in a previous
study (about 300 ng) where plain DT was coated onto the
same type of microneedle arrays (23). The high loading
Fig. 4 Confocal laser scanning microscopy (CLSM) images of 5-layer LB-MSN-DTcoated microneedles (a: DT-Alexa488; b: TMC-Rho; c: merged), and ex vivo
human skin after insertion and removal of microneedle arrays (5-layer coated) by using single (d: DT-Alexa488; e: TMC-Rho; f: merged) or multiple insertion
mode (g: DT-Alexa488; h: TMC-Rho; i: merged).
Fig. 3 Scanning electron microscopy (SEM) images of uncoated pH-sensitive microneedles (a, b1-b2), microneedles coated with 5 layers of LB-MSN-DT/TMC
(c1-c2), and the microneedles after insertion into and removal (multiple insertion mode) from ex vivo human skin (d1-d2).
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Fig. 6 DT-specific IgG1 (a, c, e)
and IgG2a (b, d, f) antibody titers
on day 21 (a, b), 42 (c, d) and 56
(e, f). Bars represent mean± SEM,
n=8. *p<0.05, **p< 0.01, ***
p<0.001.
Fig. 5 DT-specific total IgG antibody titers on day 21 (a), 42 (b) and 56 (c). Bars represent mean± SEM, n=8. *p<0.05, **p<0.01, ***p<0.001.
Pharm Res  (2018) 35:189 Page 9 of 12  189 
capacity of DT in LB-MSN-DT together with the high surface
charge of LB-MSN-DT may synergistically lead to this higher
coating amount. Additionally, the multilayer coating ap-
proach used in the current study can further increase the coat-
ed amount of antigen by increasing the number of coating
layers. By adjusting the number of coating layers, the coated
amount of nanoparticles/antigen can be tailored.
Besides the successful coating of antigen onmicroneedles, it
is important to have a fast release of the coating after the
microneedles were penetrated into skin. Here we showed that
by using a multiple insertion mode (10 penetrations within
10 s), the released amount of antigen was increased by 2.5-
fold as compared to a single insertion mode. The amount of
DT released into the skin was also increased compared to that
released from the 5 layer coatings of plain DT using a single
penetration (23). Therefore, the combination of multiple in-
sertions with nanoparticle coatings may require less coating
layers, which will facilitate the production process of coated
microneedles. When using multiple insertions, the application
time was much shorter than that used in single penetration
mode. The improvement of release efficiency may be due to
the friction force between the microneedles and the skin tissue
when the microneedles were inserted in and removed from
the skin. The short wearing time of microneedles by using the
multiple insertion mode might help improving the acceptance
by vaccinees. Nevertheless, the drawback of using the multiple
insertion mode is that a sophisticated applicator needs to be
developed. In the multilayer coating approach described in
the current study, the TMC used has strong adhesion proper-
ties and could prevent the coated nanoparticles releasing from
the microneedles (35). It would therefore be interesting to
examine polymers which have weaker electrostatic interac-
tions with the microneedles.
While hollow microneedle injected LB-MSN-DT induced
a stronger immune response as compared to plain DT, LB-
MSN-DT delivered by coated microneedles induced a com-
parable response as DT/TMC solution. The results of coated
microneedles are in contrast with those reported in a recent
study, which showed that nanoparticulate vaccine coated
microneedles induced superior immune responses as com-
pared to antigen solution intradermally delivered by a hypo-
dermic needle (36). One explanation is that the dose delivered
by coated microneedles may be lower than that delivered by
hollowmicroneedles in mice skin in vivo. However, there are at
least two arguments against this hypothesis. Firstly, our results
showed that the coated microneedles delivered a two-fold
higher (5-layer coated) or comparable (3-layer coated) dose
in ex vivo human skin, respectively, compared to that delivered
by hollowmicroneedles in human skin. The stratum corneum,
viable epidermis and dermis of mouse skin are much thinner
than that of human skin (37). However, the trigger to release
the coating from themicroneedles is the environmental pH. In
the epidermis and dermis in mouse and human skin, the pH is
7.4. Therefore, the difference of the skin thickness between
mouse and human skin is not expected to change the delivery
efficiency. Secondly, a previous study showed that the deliv-
ered amount of DT from 5-layer coated microneedles into
ex vivo human skin was similar as that delivered in ex vivomouse
skin (23). To summarize, the lower than expected responses of
coated microneedle delivered LB-MSN-DT was not likely
caused by lower dose of DT delivered.
Although the LB-MSN-DT coated microneedles induced
similar total IgG and IgG1 responses as compared to hollow
microneedle injected LB-MSN-DT on day 56 (p> 0.05), they
induced distinctly lower IgG2a responses. At the same time, it
has been reported that nano-encapsulation of antigen can
increase IgG2a responses (24,38). These results suggest that
the advantage of using nanoparticles is abrogated when they
are delivered by coated microneedles. One possible explana-
tion for the lower response induced by coated microneedles is
that the nanoparticles were not released from the
nanoparticle/TMC layers after their deposition in the skin.
As a result, the nanoparticles may be not efficiently taken up
by APCs or drained to lymph nodes. In the hollow
microneedle groups, the addition of TMC did not improve
the immune responses either. An adjuvant effect of TMC has
been reported for hypodermic needle-mediated intradermal
vaccination (39). This inconsistency may be caused by the
much lower dose of TMC used in our study.
Previous studies have shown that IgG1 titers may be mainly
responsible for the neutralizing titers against diphtheria toxin
(31). However, our results showed that although hollow
microneedle and coated microneedle groups induced IgG1
responses close to those induced by DT-Alum, they still
Fig. 7 DT-neutralizing antibody titers of mice. Results are shown for serum
collected on day 56. Bars represent mean± SEM, n=8. *p<0.05, ***
p<0.001.
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induced much lower neutralizing antibodies. These results in-
dicate that the IgG1 titers may need to reach a certain thresh-
old in order to achieve protection against diphtheria toxin.
CONCLUSION
In this study, we showed that DT loaded MSNs can be suc-
cessfully delivered into mice by using coated and hollow
microneedles, and evoke DT specific antibody responses.
When inserting coated microneedles into skin, the multiple
insertion mode of the applicator significantly increased the
release efficiency of the coating compared to the single inser-
tion mode. DT encapsulated in MSNs induced a stronger
antibody response than antigen solution when delivered by
hollow microneedles (after 1st boost), but not by coated
microneedles. Our results revealed that both the nano-
encapsulation of DT and the type of microneedles affect the
immunogenicity of the antigen.
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